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Abstract
Mechanical hyperalgesia is a clinically-relevant form of pain sensitization that develops through
largely unknown mechanisms. TRPA1, a Transient Receptor Potential ion channel, is a sensor of
pungent chemicals that may play a role in acute noxious mechanosensation and cold
thermosensation. We have developed a specific small molecule TRPA1 inhibitor (AP18) that can
reduce cinnameldehyde-induced nociception in vivo. Interestingly, AP18 is capable of reversing
CFA-induced mechanical hyperalgesia in mice. Although TRPA1-deficient mice develop normal
CFA-induced hyperalgeisa, AP18 is ineffective in the knockout mice, consistent with an on-target
mechanism. Therefore, TRPA1 plays a role in sensitization of nociception, and that compensation
in TRPA1-deficient mice masks this requirement.
Background
Sensory neurons of the dorsal root ganglia (DRGs) can
detect environmental changes through projections in the
skin. Among these primary afferent fibers, nociceptors
play an important role in sensing noxious levels of
mechanical and thermal stimuli [1]. One of the basic
properties of nociceptors is their sensitization in response
to injury and inflammation. For example, an innocuous
stimulus such as a warm shower can become painful after
sunburn, and this is called allodynia. Indeed, cold or
mechanical allodynia are serious medical problems for
patients suffering from neuropathic pain [2,3]. Hyperalge-
sia describes a similar condition, defined as an increased
response to an already painful stimulus due to injury or
inflammation.
TRPV1, a member of the Transient Receptor Potential
family of cation channels, is activated by heat, low pH,
and capsaicin [4]. TRPV1 is expressed in nociceptors, and
is sensitized in response to a variety of signal transduction
pathways activated during inflammation [5,6]. TRPV1-
deficient mice display negligible inflammatory heat
hyperalgesia [7,8]. Much less is known about molecules
involved in mechanical hyperalgesia.
Originally characterized as a noxious cold-activated ion
channel, TRPA1 is expressed in the same sensory neurons
as TRPV1, and is activated directly by diverse reactive
chemicals via covalent modification, and indirectly
through G-protein coupled receptors [9-12]. TRPA1 is
required to sense these noxious reactive chemicals in vivo;
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however, whether TRPA1 is required to sense acute nox-
ious cold and mechanical stimulus is not yet settled [13-
17]. Here, we examine the consequences of acute block of
peripheral TRPA1 for pain transduction, focusing on
mechanical hyperalgesia.
Results
To test if acute block of TRPA1 can modulate pain sensa-
tion, we sought a specific, efficient TRPA1 inhibitor.
Ruthenium red, gadolinium, menthol, and camphor can
inhibit TRPA1 activation, but also interact with other
channels, including other TRP channels[18]. Using a
Fluorometric Imaging Plate Reader (FLIPR, Molecular
Devices) calcium-influx assay, we screened 43,648 small
molecules for their ability to block cinnamaldehyde-acti-
vation of human TRPA1 in a Chinese Hamster Ovary
(CHO) cell line. We further characterized one of these
hits, AP18 ((Z)-4-(4-chlorophynyl)-3-methylbut-3-en-2-
oxime – Maybridge, Cornwall, UK; Figure 1A). AP18
blocked activation of TRPA1 by 50 μM cinnamaldehyde
with an IC50 of 3.1 μM and 4.5 μM for human and mouse
clones, respectively (Figure 1B). At concentrations up to
50 μM, AP18 was unable to appreciably block activation
of TRPV1, TRPV2, TRPV3, TRPV4, or TRPM8 (Figure 2).
AP18 blocks TRPA1 activation Figure 1
AP18 blocks TRPA1 activation. (A) Chemical structures of the AP18 (upper) and cinnamaldehyde (lower). (B) Dose-response 
relationships for block of the calcium influx by AP18 into CHO cells expressing mouse and human TRPA1 elicited by 50 μM 
cinnamaldehyde (left panel). Calcium influx was measured using a standard FLIPR assay, data points are the average of four 
wells (~8,000 cells/well) and error bars show standard error. Values are normalized to the maximal response (observed in the 
absence of AP18). (C) Ratiometric Ca2+ imaging of average of ~50 mTRPA1-expressing CHO cells in response to 1 mM Iodoa-
cetamide (IA) and 100 μM of AP18 (black trace). Grey trace represents cells that were treated with IA alone. (D) Current-
voltage relationship of TRPA1. Outward rectifying currents elicited by cinnamaldehyde (left panel) in inside-out macropatches 
derived from TRPA1-expressing Xenopus oocytes were suppressed by AP18 coapplications (right panel).Molecular Pain 2007, 3:40 http://www.molecularpain.com/content/3/1/40
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AP18 reversibly blocked mouse TRPA1 responses to
iodoacetamide (an irreversible cysteine-alkylating agent)
in CHO cells assayed by ratiometric Ca2+ imaging (Figure
1C). AP18 also blocked cold- and mustard-oil-induced
activation of mouse TRPA1 (data not shown). Moreover,
AP18 blocked cinnamaldehyde-induced TRPA1 currents
in excised patches from Xenopus oocytes (Figure 1D). In
vivo, 1–10 mM of AP18 injected in hindpaw of mice did
not cause any obvious behavioural responses (data not
shown). Importantly, AP18 significantly blocked cin-
namaldehdye-induced but not capsaicin-induced nocice-
ptive events, demonstrating efficacy and specificity
(Figure 3).
Sensitization of nociceptive neurons is the basis for many
chronic pain states [1]. To investigate the role of TRPA1 in
pain sensitization, we tested AP18 in mechanical hyperal-
gesia induced by complete Freund's adjuvant (CFA).
Mechanical sensitivity was measured using an automated
Von Frey apparatus which records the point at which the
paw is withdrawn in response to a progressively-increas-
ing force. AP18 but not vehicle solution injected in the
paw 24 hours after CFA treatment almost completely
reversed mechanical hyperalgesia (Figure 4A). AP18 did
not reverse CFA-induced heat hyperalgesia (Figure 5).
Acute nociceptive responses to both increasing mechani-
cal force and infrared noxious heat applications to the
paw without coincident inflammation were not affected
by AP18 treatment (data not shown). Remarkably, AP18
did not reverse CFA-induced mechanical hyperalgesia in
TRPA1-deficient mice, suggesting on-target mechanisms
for the activity of AP18 (Figure 4B) [16,17]. It is important
to note that prior to AP18 treatment, TRPA1-deficient
mice developed normal CFA-induced mechanical hyper-
algesia (Figure 4B), suggesting that compensation in these
AP18 suppresses acute nociceptive behaviours caused by cinnamaldehyde but not capsaicin Figure 3
AP18 suppresses acute nociceptive behaviours caused by cinnamaldehyde but not capsaicin. Time spent licking and flicking 
hindpaws injected with cinnamaldehyde (16.4 mM) or capsaicin (0.328 mM) was measured for five minutes and compared with 
animals co-injected with AP18 (1 mM). Numbers of cases for each experiment from the left is 8, 8, 6 and 6, respectively (*p < 
0.05, two-tailed Student's t-test).
AP18 specifically blocks TRPA1 Figure 2
AP18 specifically blocks TRPA1. Calcium influx (FLIPR) 
in HEK cells transiently transfected with the indicated 
cDNAs in response to 200 nM capsaicin (TRPV1), 150 μM 2-
APB (TRPV2), 30 μM 2-APB (TRPV3), 20 μM 4alpha-PDD 
(TRPV4), 20 μM menthol (TRPM8), and 80 μM cinnamalde-
hyde (TRPA1). Values are given as a percentage of agonist 
response in the absence of AP18.Molecular Pain 2007, 3:40 http://www.molecularpain.com/content/3/1/40
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mice masks the requirement for TRPA1 in mechanical sen-
sitization (see discussion below). Also note that TRPA1-
deficient mice do not show significantly increased acute
mechanical threshold before CFA application in this assay
(Figure 4B). However, we do observe the previously-
reported deficit in acute mechanosensation in TRPA1-
deficient mice at higher g-forces when using the protocol
of Kwan et al.(2006) which assays frequency of paw with-
drawal in response to a fixed (rather than increasing) force
applied to the paw (Figure 6) [16]. In addition to the acute
mechanosensory phenotype, TRPA1-deficient mice have
strong deficits in bradykinin-induced inflammatory pain
[16,17]. As expected, AP18-treated mice showed reduced
bradykinin-induced mechanical hyperalgesia compared
to vehicle (Figure 7).
Whether TRPA1 is activated by noxious cold tempera-
tures, and whether TRPA1-deficient mice show deficits in
cold thermosensation is unsettled, and area of active
research [9,16,17,19-22]. We have found it difficult to
demonstrate noxious cold response in wildtype mice
using temperatures as low as 0°C, either alone or follow-
ing CFA injection (data not shown). Sprague Dawley rats,
on the other hand, readily display cold hyperalgesia, and
TRPA1 is implicated in this process [21]. CFA-induced
cold hyperalgesia assayed on a 5°C plate is significantly
reversed in rats treated with AP18, supporting a role of
TRPA1 in cold nociception (Figure 8).
Discussion
The consequence of acute pharmacological block of pro-
tein activity in adult animals sometimes deviates from the
effects of germline ablation of the encoding gene. For
example, it was recently shown that pharmacological
inhibition of TRPV1 induces hyperthermia in wildtype
mice in a TRPV1-dependent manner, although mice born
genetically-deficient in TRPV1 do not display a hyperther-
AP18 does not reverse CFA-induced heat hyperalgesia Figure 5
AP18 does not reverse CFA-induced heat hyperalgesia. Same 
designation of symbols as in Figure 4A is used. Arrow indi-
cates time of AP18 (or vehicle) injections. Paw-withdrawal 
latencies to infrared 20 setting are measured and averaged (n 
= 8).
TRPA1 is involved in CFA-induced mechanical hyperalgesia Figure 4
TRPA1 is involved in CFA-induced mechanical hyperalgesia. 
(A) AP18 reverses CFA-induced mechanical hyperalgseia in 
wildtype mice (n = 8). Red symbols represent the paws 
treated with CFA. 24 hours later, mechanical sensitivity was 
assayed again ("after CFA" timepoint), and the same paws 
were injected with either AP18 (red circles) or vehicle (red 
triangle). Mechanical sensitivity was again monitored during 
the next four hours. Blue symbols represent the control 
uninjected paws. (B) AP18 reverses mechanical hyperalgesia 
in wildtype (red) but not TRPA1-deficient (green) littermates 
(n = 12, females). Same protocol as (A), data from CFA- and 
AP18-injected paws shown. Arrows indicate time of AP18 
(or vehicle) injections. ***p < 0.001, **p < 0.01, *p < 0.05, 
two-tailed Student's t-test.Molecular Pain 2007, 3:40 http://www.molecularpain.com/content/3/1/40
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mic phenotype [23,24]. Using a small molecule inhibitor
of TRPA1 we have demonstrated a novel role of TRPA1 in
mechanical hyperalgesia. AP18 is ineffective in reversing
CFA-induced mechanical hyperalgesia in TRPA1-deficient
mice, suggesting an on-target mechanism for AP18. What
compensatory mechanisms may account for the normal
mechanical hyperalgesia observed in TRPA1-deficient
mice? Upregulation of another protein that plays a similar
role as TRPA1 (molecular compensation) is one explana-
tion. TRPA1 is the only member of the TRPA family in
mammals, and TRPV1, another nocisensor expressed in
pain-sensing neurons, does not appear to be upregulated
in TRPA1-deficient mice, although the two channels func-
tionally interact [16,17,25]. TRPV4, a related ion channel,
has been implicated in some forms of mechanical hyper-
algesia and can be an intriguing candidate [26]. However,
whether TRPV4 expression is required in skin cells or
DRGs is unsettled [27]. Cellular compensation (i.e. a
change in the composition of neuronal subtypes or in
neuronal connectivity) is another potential explanation
for the normal hyperalgesia observed in TRPA1-deficient
mice. Furthermore, it is possible that TRPA1 is involved in
the maintenance of mechanical hyperalgesia rather than
its induction. In this case, normal development of
Bradykinin (BK)-induced mechanical hyperalgesia is partially  blocked by AP18 Figure 7
Bradykinin (BK)-induced mechanical hyperalgesia is partially 
blocked by AP18. Same designation of symbols as in Figure 
4A is used; however, BK (instead of CFA) is co-injected with 
AP18 in wildtype mice, and mechanical sensitivity is meas-
ured within 15 minutes (n = 12). Arrow indicates time of 
AP18 (or vehicle) injections. ***p < 0.001, *p < 0.05, two-
tailed Student's t-test.
Acute mechanosensory phenotype in TRPA1-deficient mice Figure 6
Acute mechanosensory phenotype in TRPA1-deficient mice. Frequency of paw withdrawal to fixed forces applied to the hind-
paw is measured. 13 WT and 11 TRPA1-deficient male mice were tested. Briefly, hindpaws were exposed to the force actuator 
starting with the greatest force. Each force was applied eight times at ~1/s. The actual g-force values used differ between this 
study and Kwan et al. (2006) probably due to the use of different instrumentation [16].Molecular Pain 2007, 3:40 http://www.molecularpain.com/content/3/1/40
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mechanical hyperalgesia is expected in TRPA1-deficient
mice, but compensation could contribute to maintenance
of the condition.
TRPA1 is specifically expressed in nociceptors, its tran-
scripts are upregulated in response to CFA in rats, and
inflammatory signals sensitize the channel, consistent
with TRPA1 being involved in hyperalgesia [21,28,29].
The mechanism by which TRPA1 contributes specifically
to mechanosensation is less clear [30]. It is possible that
mammalian TRPA1 is directly activated by mechanical
forces, although no such data is currently present. Alterna-
tively, mechanical damage could indirectly activate
TRPA1 through release of reactive compounds or intracel-
lular calcium (both of which can directly activate mam-
malian TRPA1) [11,12,31]. One other possibility is that
TRPA1 is involved in modulation of mechanosensory sig-
naling, and not directly involved with mechanotransduc-
tion. Interestingly, the ortholog of mammalian TRPA1 in
C. elegans can be activated by pressure applied through a
recording pipette when expressed in heterologous cells
(although it is also not clear if cTRPA1 is directly or indi-
rectly responding to this mechanical force) and plays an
essential role in mechanosensory behaviour [32].
In conclusion, this study highlights a novel role of mouse
TRPA1 in mechanical hyperalgesia, and underscores the
importance of considering both acute pharmacological
block and genetic ablations in assigning gene function.
Methods
FLIPR Screen and Calcium imaging
CHO cells expressing human TRPA1 were plated into 384-
well plates at a concentration of ~8,000 cells/well. Cells
were transferred to phosphate-buffered saline (PBS) and
loaded with the calcium sensitive dye FLUO-4 using the
FLIPR Calcium 3 Assay Kit (Molecular Devices, Sunnyvale,
CA) one hour prior to the assay. Assays were run using the
FLIPR2 (Molecular Devices, Sunnyvale, CA). All com-
pounds were diluted into PBS from a high concentration
DMSO-based stock solution and added during data col-
lection with the FLIPR2 internal pipette head. Final
DMSO concentrations never exceeded 0.5%. Ratiometric
Ca2+ imaging on tet-inducible mouse TRPA1 in CHO cells
was performed as described[9].
Xenopus oocyte excised patches
Human TRPA1 was cloned into the pOX expression vector
and cRNA transcripts were produced using the T3 mMes-
sage Machine kit (Ambion, TX)[33]. Mature defolliculated
Xenopus  o o c y t e s  w e r e  i n j e c t e d  w i t h  5 0  n L  o f  h u m a n
TRPA1 cRNA at ~1 μg/μL. Oocytes were incubated in
ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM
CaCl2, 5 mM HEPES, pH 7.4, supplemented with Na-
pyruvate (2.5 mM), penicillin (100 u/mL) and streptomy-
cin (100 μg/mL) for three to five days to ensure sufficient
TRPA1 expression. Vitelline envelopes were mechanically
removed prior to experiments. Recordings were made
under voltage clamp from excised patches in the inside-
out configuration at room temperature with 1–1.5 MΩ
pipettes. The bath ground was isolated using an agar
bridge. Capacitance and series resistance were compen-
sated and solutions that eliminate native calcium-acti-
vated chloride currents were used (Patch electrode (in
mM): 140 NaMES, 4 NaCl, 1 EGTA, 10 HEPES, pH 7.2;
bath solution: 140 KMES, 4 KCl, 1 EGTA, 10 HEPES, pH
7.2). Compounds were added to the bath solution. Cur-
rents were recorded using a Multiclamp 700B amplifier
and the pCLAMP acquisition suite.
Behavioral assays
Mice of 6–16 weeks in age and 150–250 g Sprague Dawley
rats were used for all behavioural assays. C57BL6/J mice
were used, except in Figure 3b: TRPA1-deficient mice and
WT littermates were on mixed genetic background [16].
Animals were acclimated for 20–60 min to their testing
environment prior to all experiments. Student's t- test was
used for all statistical calculations. All error bars represent
standard error of the mean (SEM). Hargreaves apparatus
(Plantar Analgesia meter) and Von Frey apparatus
AP18 partially reverses cold hyperalgesia in rats treated with  CFA Figure 8
AP18 partially reverses cold hyperalgesia in rats treated with 
CFA. Same designation of symbols as Figure 4A is used. 
Number of flicks, licks, paw raises are counted for 10 min-
utes and averaged on a 5°C cold plate (n = 8). Arrow indi-
cates time of AP18 (or vehicle) injections. *p < 0.05, two-
tailed Student's t-test.Molecular Pain 2007, 3:40 http://www.molecularpain.com/content/3/1/40
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(Dynamic Plantar Aesthesiometer) are from UGO Basile.
Mechanical or thermal hyperalgesia assays were per-
formed as described [7,34]. Briefly, mice were acclimated
for 60 minutes to the testing environment prior to all
experiments. Baseline responses were measured first and
then 10 nM BK in 20 μl was injected to the skin of left
hindpaws. Von Frey threshold or paw withdrawal latency
was measured at 5, 15 and 30 minutes post injection. 1
mM of AP18 was coinjected to left hindpaws to test its
analgesic effect. For CFA-induced hyperalgesia testing, 10
μg CFA in 10 μL was injected into mice and 50 μg in 100
μL (1:1 emulsion of mineral oil and saline) was injected
into rats and 24-hour measurements were performed
[7,21,35]. 1 mM of AP18 was injected in 10 μl. Control
and AP18 solutions were in PBS, 0.5% Tween80 and 1%
DMSO. Before the measurements, animals were re-accli-
mated to the environment for 20–60 minutes. Different
time points were used for experiments with CFA-injected
animals (30 min, 1, 1 1/2, 2 and 4 hr after AP18 injec-
tion).
Chemicals
All chemicals were purchased from Sigma-Aldrich unless
otherwise described. Capsaicin was purchased from Fluka.
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